Download PDF


I have been in the lab of Carlos Cordon-Cardo at the Herbert Irving Comprehensive Cancer Center (HICCC) of the Columbia University Medical Center.  My interests have been in the molecular biology of cancer, with specific interests in the contribution of cancer stem cells to tumorigenesis.   As a graduate student in the Integrated Program for Cellular, Molecular, Structural and Genetic Studies, I have had a broad set of experiences in the lab.  I'm quite comfortable with all of the skills listed in my c.v., including, tissue culture, Westerns, ELISA and FACS analysis, as well as gene transfection/expression and IHC/ICC/IF.   Before pursuing my graduate studies I was a Study Director and Project Manager, and then Scientist, in a translational cancer program at The Rogosin Institute (New York, NY). I was fortunate enough to be involved in great science and to oversee the transition of that research into production for human clinical trials.  I was intimately involved in preparing the Investigational New Drug (IND) application for the product, which was successful.  I was also the lead for installing quality systems (cGMP and GLP) in collaboration with our quality department.  The cancer product is currently in Phase-II trials, after successfully completing Phase-I.  We recently published two peer reviewed scientific articles (see c.v.) and the project was the subject of an article in the Wall Street Journal last month.   Lastly, I should mention that while I was a doctoral candidate in Carlos' lab I had to take a leave of absence when my daughter became seriously, and ultimately terminally ill with leukemia (AML). While I have been offered an opportunity to return to Columbia to complete my thesis, I am also taking this time to consider other opportunities.  For a variety of practical reasons, my intention is to return to industry without completing my doctorate at Columbia.  I would be happy to discuss my qualifications, and any opportunities, at any time. 

Work experience

Nov 1997Present


The Rogosin Institute

I began my tenure with The Rogosin Institute at it's Xenia, Ohio laboratory, as a lab technician, first in its diabetes research project (Islet Isolation Laboratory), then in its cancer research laboratory.  While most of Rogosin's operations are in New York City, these labs were investigating cell encapsulation technology for human medical use. In the cancer project I became the project manager and study director for pre-clinical trials of a product we called the "cancer macrobead".  I began reporting directly to Barry Smith, M.D., Ph.D., now the President/Director of The Rogosin Institute.  I was supervising a talented group of about seven other technicians.  We developed this technology into a promising cancer therapy and submitted an Investigational New Drug (IND) application to the FDA in 2003.  The application was ultimately approved and the product is currently in phase-2 human trials, after successfully completing phase-1 trials.  

In 2003 Rogosin's cancer project was transitioning from a research phase to a production phase, and in the previous years I had the opportunity to work with a new Quality team to supervise the installation of a quality system into our operations.  This was a huge endeavor and a valuable experience. 

As we completed the transition to production in Xenia, much of the science and molecular biology of the project was shifting to the facilities in Manhattan, at Rockefeller University, and New York Presbyterian/Cornell Medical School.  I was offered the opportunity to join the team there and given the flexibility to pursue my graduate education at Columbia University.  While my graduate research interests were separate and did not involve Rogosin, I was able to help Rogosin to continue a research collaboration in the laboratory of Carlos Cordon-Cardo at Columbia, which we had begun in his lab at Memorial Sloan-Kettering Cancer Center.  


Sep 2003Sep 2009


Columbia University


Genomics: RT-PCR, Northern, and gene chip array analysis, molecular cloning/expression Proteomics: Quantitative Westerns, ELISA, dot blots, antibody generation/characterization, immunoprecipitation  Cell culture: epithelial, carcinoma, neuronal (primary embryonic rat), embryonic stem cell, biogel encapsulation, transfection, stable and inducible cell line generation, RNAi, lentivirus design/production/infection. Cell biology: live cell imaging, transport, axon/dendrite outgrowth/branching, cell migration, FACS analysis and cell sorting, cell proliferation bioassays Microscopy: immunohistochemistry/immunocytochemistry, immunofluorescence, morphometerics (Metamorph, etc.), live imaging